**Philippines**

**Population 2016** 103 million

<table>
<thead>
<tr>
<th>Estimates of TB burden*, 2016</th>
<th>Number (thousands)</th>
<th>Rate (per 100 000 population)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mortality (excludes HIV+TB)</td>
<td>22 (22–22)</td>
<td>21 (21–22)</td>
</tr>
<tr>
<td>Mortality (HIV+TB only)</td>
<td>0.3 (0–2.6)</td>
<td>0.29 (0–2.5)</td>
</tr>
<tr>
<td>Incidence (includes HIV+TB)</td>
<td>573 (321–895)</td>
<td>554 (311–868)</td>
</tr>
<tr>
<td>Incidence (HIV+TB only)</td>
<td>6 (2.5–11)</td>
<td>5.9 (2.4–11)</td>
</tr>
<tr>
<td>Incidence (MDR/RR-TB)**</td>
<td>30 (21–40)</td>
<td>30 (20–39)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Estimated TB incidence by age and sex (thousands)*, 2016</th>
<th>0-14 years</th>
<th>&gt; 14 years</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Females</td>
<td>33 (16–50)</td>
<td>136 (68–205)</td>
<td>169 (84–255)</td>
</tr>
<tr>
<td>Males</td>
<td>37 (18–56)</td>
<td>366 (182–550)</td>
<td>403 (200–606)</td>
</tr>
<tr>
<td>Total</td>
<td>70 (35–106)</td>
<td>502 (249–755)</td>
<td>573 (321–885)</td>
</tr>
</tbody>
</table>

**TB case notifications, 2016**

- Total cases notified: 345 144
- Total new and relapse: 332 941
- % with known HIV status: 19%
- % pulmonary: 99%
- % bacteriologically confirmed among pulmonary: 37%

**Universal health coverage and social protection**

- TB treatment coverage (notified/estimated incidence), 2016: 58% (37–100)
- TB case fatality ratio (estimated mortality/estimated incidence), 2016: 0.04 (0.02–0.06)

**TB/HIV care in new and relapse TB patients, 2016**

- Patients with known HIV-status who are HIV-positive: 1 009 2%
- on antiretroviral therapy: 820 81%

**Drug-resistant TB care, 2016**

- Estimated MDR/RR-TB cases among notified pulmonary TB cases: 20 000 (15 000–24 000)
- Estimated % of TB cases with MDR/RR-TB: 2.6% (1.8–3.3)
- % notified tested for rifampicin resistance: 7% 67% 50 752
- MDR/RR-TB cases tested for resistance to second-line drugs: 432
- Laboratory-confirmed cases
  - MDR/RR-TB: 5 233, XDR-TB: 5
  - Patients started on treatment ****
  - MDR/RR-TB: 5 253, XDR-TB: 5

**Treatment success rate and cohort size**

- New and relapse cases registered in 2015: 91% 263 481
- Previously treated cases, excluding relapse, registered in 2015: 82% 7 925
- MDR/RR-TB cases started on second-line treatment in 2014: 46% 2 490
- XDR-TB cases started on second-line treatment in 2014: 0% 7

**TB financing, 2017**

- National TB budget (US$ millions): 104
- Funding source: 19% domestic, 53% international, 28% unfunded

* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2016 and patients who were not laboratory-confirmed

Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.

Generated: 2018-06-02

Data: www.who.int/tb/data